Clostridioides difficile infection: antimicrobial prescribing

Resource impact statement

No significant resource impact is anticipated

NICE has recommended vancomycin and fidaxomicin for treatment of Clostridioides difficile (C. difficile) infection.

We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).

Implementing the guideline is anticipated to lead to an increase in the use of oral vancomycin and oral fidaxomicin. The overall resource impact is not expected to be significant at a national level.

A resource impact template is provided for completion at a local level to allow the potential resource impact of implementing any prescribing changes to be assessed.

Treatment for C.difficile infection is commissioned by integrated care systems / clinical commissioning groups and strategic transformation partnerships. Providers are NHS hospital trusts, community providers and GPs.